Cyfuse Biomedical K.K.

Tokyo Stock Exchange 4892.T

Cyfuse Biomedical K.K. Shareholders' Equity for the year ending December 31, 2023: USD 22.70 M

Cyfuse Biomedical K.K. Shareholders' Equity is USD 22.70 M for the year ending December 31, 2023, a -21.01% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Cyfuse Biomedical K.K. Shareholders' Equity for the year ending December 31, 2022 was USD 28.74 M, a 74.14% change year over year.
  • Cyfuse Biomedical K.K. Shareholders' Equity for the year ending December 31, 2021 was USD 16.50 M, a 10.07% change year over year.
  • Cyfuse Biomedical K.K. Shareholders' Equity for the year ending December 31, 2020 was USD 14.99 M.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
SV Wall Street
Tokyo Stock Exchange: 4892.T

Cyfuse Biomedical K.K.

CEO Ms. Shizuka Akieda
IPO Date Dec. 1, 2022
Location Japan
Headquarters Sumitomo Fudosan Mita Twin Building
Employees 21
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.

StockViz Staff

January 31, 2025

Any question? Send us an email